Silence Therapeutics plc (SLN) Financial Ratios
30 years of historical data (1996–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: 95.91
30Y Low95.9·High95.9
P/B Ratio
↓
N/A
—
5yr avg: 25.26
30Y Low0.8·High83.1
ROE
↑
-247.1%
↓+3% vs avg
5yr avg: -255.8%
30Y Low-448%·High-3%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
SLN Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Silence Therapeutics plc currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $328M | $287M | $106M | $215M | $164M | $708M | $600M | — | — | — | — |
| Enterprise Value | $317M | $276M | $-15144639 | $146M | $109M | $635M | $573M | — | — | — | — |
| P/E Ratio → | -3.68 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 587.26 | 513.72 | 2.45 | 8.46 | 7.56 | 57.06 | 109.45 | — | — | — | — |
| P/B Ratio | — | — | 0.79 | 9.77 | 7.41 | 83.08 | 66.20 | — | — | — | — |
| P/FCF | — | — | — | — | — | 95.91 | — | — | — | — | — |
| P/OCF | — | — | — | — | — | 77.11 | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
SLN EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 493.26 | -0.35 | 5.77 | 5.05 | 51.14 | 104.50 | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | 85.97 | — | — | — | — | — |
SLN Profitability
Margins and return-on-capital ratios measuring operating efficiency
Silence Therapeutics plc earns an operating margin of -16056.0%. Operating margins have compressed from -195.5% to -16056.0% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -247.1% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 61.5% | 61.5% | 72.7% | 59.3% | 37.8% | 39.9% | 31.3% | 100.0% | — | -49543.8% | -1031.3% |
| Operating Margin | -16056.0% | -16056.0% | -146.4% | -195.5% | -281.9% | -369.0% | -654.3% | -9317.2% | — | -89943.8% | -1546.2% |
| Net Profit Margin | -15851.9% | -15851.9% | -104.7% | -170.5% | -232.4% | -317.4% | -594.0% | -8025.4% | — | -10112.5% | -1096.1% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -247.1% | -247.1% | -58.1% | -196.4% | -329.0% | -448.2% | -217.2% | -70.0% | -42.1% | -3.0% | -14.7% |
| ROA | -53.0% | -53.0% | -28.1% | -38.1% | -49.4% | -43.3% | -49.3% | -46.1% | -39.2% | -2.9% | -14.4% |
| ROIC | — | — | -370.7% | — | — | — | — | -160.5% | -133.2% | -87.1% | -75.4% |
| ROCE | -54.3% | -54.3% | -44.8% | -54.3% | -73.3% | -64.8% | -74.0% | -63.6% | -47.1% | -27.0% | -20.8% |
SLN Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $11M exceeds total debt of $-160000, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.00 | 0.02 | 0.02 | 0.02 | 0.04 | 0.01 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | -0.90 | -3.11 | -2.46 | -8.61 | -2.99 | -0.63 | -0.61 | -0.82 | -0.72 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | -9.94 | — | -7.70 | — | — | — |
| Interest Coverage | — | — | — | -1458.94 | -1298.72 | -5726.75 | -2240.44 | -688.91 | — | -959.40 | — |
Net cash position: cash ($11M) exceeds total debt ($-160000)
SLN Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio has improved from 4.62x to 11.14x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | — | — | 11.14 | 4.62 | 4.41 | 5.69 | 2.99 | 3.88 | 7.70 | 17.14 | 26.09 |
| Quick Ratio | — | — | 11.14 | 4.62 | 4.41 | 5.69 | 2.99 | 3.88 | 8.34 | 18.08 | 27.95 |
| Cash Ratio | — | — | 8.76 | 3.08 | 3.24 | 4.85 | 1.46 | 3.47 | 6.93 | 16.21 | 24.23 |
| Asset Turnover | — | 0.00 | 0.21 | 0.21 | 0.20 | 0.13 | 0.06 | 0.01 | — | 0.00 | 0.01 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | 227.04 | 344.89 | 15.42 | 9.73 | 1952.31 | 5.98 | — | — | 383.96 |
SLN Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Silence Therapeutics plc does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | 1.0% | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Shares Outstanding | — | $47M | $15M | $12M | $11M | $30M | $27M | $25M | $23M | $23M | $23M |
Peer Comparison
Compare SLN with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 SLNYou | $328M | -3.7 | — | — | 61.5% | -16056.0% | -247.1% | — | — |
 ALNY | $39B | 127.0 | 70.2 | 84.8 | 81.8% | 13.5% | 73.3% | 33.4% | 2.3 |
 ARWR | $11B | -6389.3 | 90.4 | 69.6 | 97.1% | 11.9% | -0.5% | 9.3% | 3.0 |
 SRPT | $2B | -2.9 | — | — | 59.9% | -29.9% | -53.5% | -31.4% | — |
 NTLA | $2B | -3.6 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 IONS | $13B | -31.9 | — | — | 98.3% | -40.5% | -70.7% | -12.8% | — |
 REGN | $74B | 17.1 | 17.8 | 18.1 | 85.4% | 24.9% | 14.9% | 8.9% | 0.7 |
 MDGL | $12B | -41.6 | — | — | 94.1% | -31.3% | -42.5% | -29.4% | — |
 AKRO | $4B | -14.6 | — | — | — | — | -39.2% | -55.3% | — |
 VKTX | $4B | -9.9 | — | — | — | — | -47.3% | -44.4% | — |
 AZN | $283B | 27.9 | 15.8 | 24.1 | 81.9% | 23.4% | 22.9% | 14.9% | 1.5 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
See SLN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SLN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SLN vs ALNY
Side-by-side business, growth, and profitability comparison vs Alnylam Pharmaceuticals, Inc..
Start ComparisonSLN — Frequently Asked Questions
Quick answers to the most common questions about buying SLN stock.
What is Silence Therapeutics plc's P/E ratio?
Silence Therapeutics plc's current P/E ratio is -3.7x. This places it at the 50th percentile of its historical range.
What is Silence Therapeutics plc's ROE?
Silence Therapeutics plc's return on equity (ROE) is -247.1%. The historical average is -80.0%.
Is SLN stock overvalued?
Based on historical data, Silence Therapeutics plc is trading at a P/E of -3.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Silence Therapeutics plc's profit margins?
Silence Therapeutics plc has 61.5% gross margin and -16056.0% operating margin.